You will be redirected to:
Paris 9th January, 2023 (France) - Today, EvidentIQ, a leading clinical data science group and Keyrus Life Science, the international Connected Contract Research Organization (C²RO), announced the signing of a strategic partnership. The synergy between both companies will improve automation, efficiency and agility in clinical research by leveraging new eClinical capabilities.
EvidentIQ, based in Hamburg, is a leading clinical data science group, offering state-of-the art eClinical solutions (eConsent, EDC, CTMS, eCOA, RWE).
Keyrus Life Science, operating across Europe and North America, connects CRO expertise, life data science and digital enablement to fully leverage both clinical research ecosystems and real-world evidence to help organizations shape better their clinical research trial strategies.
“I’m very proud to be able to announce today the formation of a strategic partnership between EvidentIQ and Keyrus Life Science. I strongly believe that it will transform the industry and create significant value for our customers as they will benefit from receiving industry leading eClinical technology, Real World Evidence and a world-class, full service model on one hand.” says Andreas Weber, CEO at EvidentIQ.
“Thanks to this partnership, Keyrus Life Science and EvidentIQ will be able to digitally empower and operate clinical research on a new level, offering life science companies the capability to access enhanced reactivity, flexibility and get the full value from their data in the development of new drugs and therapies” states Michael Attlan, VP Life Science at Keyrus, “This synergy and the complementary offerings between our two companies are both key success factors in delivering practical and efficient solutions for our clients in clinical research”.